A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying ...

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.